You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

344 Results
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant
Apr 2023
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Nov 2020
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • goserelin
Mar 2016
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Apr 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • leuprolide - long-acting formulation
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant, Palliative
Sep 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Jan 2023
Regimen
Intent: Palliative, Adjuvant
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
ODB - General Benefit
  • bicalutamide
Oct 2016

Pages